

Literatur zum Artikel

Periphere arterielle Verschlusskrankheit – was moderne Gefäßchirurgie leisten kann

1. Herold G (2019) Innere Medizin 2020
2. Criqui MH, Aboyans V (2015) Epidemiology of peripheral artery disease. *Circ Res* 116: 1509–1526
3. Conte MS, et al (2019) Global vascular guidelines on the management of chronic limb-threatening ischemia. *Eur J Vasc Endovasc Surg* 58: S1eS109
4. Pomposelli FB, Kansal N, Hamdan AD, et al (2003) A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. *J Vasc Surg* 37: 307–315
5. Norgren L, Hiatt WR, Dormandy JA, et al (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). *Eur J Vasc Endovasc Surg* 33 Suppl 1: S1–75
6. Wieker CM, Schönefeld E, Osada N, et al (2016) Results of common femoral artery thromboendarterectomy evaluation of a traditional surgical management in the endovascular era. *J Vasc Surg* 64: 995–1001
7. Uhl C, Götzke H, Zeman F, et al (2020) Long-term outcome of common femoral artery endarterectomy in octogenarians and non-octogenarians. *Scand J Surg* 25: 1457496920907733. doi: 10.1177/1457496920907733 [Epub ahead of print]
8. Kalman PG, Walker PM, Johnston KW (1991) Consequences of groin lymphatic fistulae after vascular reconstruction. *Vasc Endovasc Surg* 25: 201–203
9. Tyndall SH, Shepard AD, Wilczewski JM, et al (1994) Groin lymphatic complications after arterial reconstruction. *J Vasc Surg* 19: 858–863
10. Uhl C, Götzke H, Woronowicz S, et al (2020) Treatment of lymphatic complications after common femoral artery endarterectomy. *Ann Vasc Surg* 62: 382–386
11. Uhl C, Betz T, Pfister K, et al (2019) Remote iliac artery endarterectomy with selective stent use at the proximal dissection zone in TransAtlantic Inter-Society Consensus C and D lesions. *J Vasc Surg* 69: 1143–1149
12. Cintora I, Pearce DE, Cannon JA (1988) A clinical survey of aortobifemoral bypass using two inherently different graft types. *Ann Surg* 208: 625–630
13. Samson RH, Morales R, Showalter DP, et al (2016) Heparin-bonded expanded polytetrafluoroethylene femoropopliteal bypass grafts outperform expanded polytetrafluoroethylene grafts without heparin in a long-term comparison. *J Vasc Surg* 64: 638–647
14. Daenens K, Schepers S, Fournieu I, et al (2009) Heparin-bonded ePTFE grafts compared with vein grafts in femoropopliteal and femorocrural bypasses: 1- and 2-year results. *J Vasc Surg* 49: 1210–1216
15. Uhl C, Hock C, Betz T, et al (2015) Comparison of venous and HePTFE tibial and peroneal bypasses in critical limb ischemia patients unsuitable for endovascular revascularization. *Vascular* 23: 607–613
16. Töpel I, Stigler T, Ayl I, et al (2017) Biosynthetic grafts to replace infected prosthetic vascular bypasses: a single-center experience. *Surg Infect* 18: 202–205
17. De Caridi G, Massara M, David A, et al (2016) Spinal cord stimulation to achieve wound healing in a primary lower limb critical ischaemia referral centre. *Int Wound J* 13: 220–225
18. Ubbink DT, Vermeulen H, Spincemaille GH, et al (2004) Systematic review and meta-analysis of controlled trials assessing spinal cord stimulation for inoperable critical leg ischaemia. *Br J Surg* 91: 948–955
19. Dick P, Barth B, Mlekusch W, et al (2008) Complications after peripheral vascular interventions in octogenarians. *J Endovasc Ther* 15: 383–389
20. Kudo T, Chandra FA, Ahn SS (2005) The effectiveness of percutaneous transluminal angioplasty for the treatment of critical limb ischemia: a 10-year experience. *J Vasc Surg* 41: 423–435
21. Tepe G, Laird J, Schneider P, et al (2015) Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. *Circulation* 131: 495–502
22. Marmagkiolis K, Hakeem A, Choksi N, et al (2014) 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty. *Catheter Cardiovasc Interv* 84: 555–564
23. Brodmann M, Keirse K, Scheinert D, et al (2017) Drug-coated balloon treatment for femoropopliteal artery disease: the IN.PACT global study de novo in-stent restenosis imaging cohort. *JACC Cardiovasc Interv* 10: 2113–2123
24. Langhoff R, Behne A, Buschmann E (2016) Promising role of drug-coated balloons in the tibial vessels? *J Cardiovasc Surg* 57: 667–676
25. Katsanos K, Spiliopoulos S, Kitrou P, et al (2018) Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc* 7: e011245
26. Ouriel K, Adelman MA, Rosenfield K, et al (2019) Safety of paclitaxel-coated balloon angioplasty for femoropopliteal peripheral artery disease. *JACC Cardiovasc Interv* 12: 2515–2524
27. Mwipatayi BP, Sharma S, Daneshmand A, et al (2016) Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. *J Vasc Surg* 64: 83–94
28. Liistro F, Angioli P, Porto I, et al (2019) Drug-eluting balloon versus drug-eluting stent for complex femoropopliteal arterial lesions: The DRASTICO Study. *J Am Coll Cardiol* 74: 205–215
29. Stavroulakis K, Bisdas T, Torsello G, et al (2015) Combined directional atherectomy and drug-eluting balloon angioplasty for isolated popliteal artery lesions in patients with peripheral artery disease. *J Endovasc Ther* 22: 847–852
30. Rümenapf G, Morbach S (2014) What can I do with a patient with diabetes and critically impaired limb perfusion who cannot be revascularized? *Int J Low Extrem Wounds* 13: 378–389